trending Market Intelligence /marketintelligence/en/news-insights/trending/DicLe7aNv5_vpfRHN7sLNQ2 content esgSubNav
In This List

TherapeuticsMD submits FDA application for hot flash drug

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


TherapeuticsMD submits FDA application for hot flash drug

TherapeuticsMD Inc. submitted a new drug application to the U.S. Food and Drug Administration for TX-001HR to treat moderate-to-severe vasomotor symptoms, or hot flashes and night sweats, due to menopause.

The treatment is a bio-identical hormone therapy combination of estradiol and progesterone in an oral softgel. Vasomotor symptoms arising from menopause include night sweats, hot flashes and flushes.

The submission is supported by positive results from the phase 3 Replenish trial of TX-001HR. TherapeuticsMD expects to hear back from the FDA about 74 days after the application's submission.